Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data

Development of a Tool to Measure the Clinical Response to Biologic Therapy in Uncontrolled Severe Asthma: The FEV1, Exacerbations, Oral Corticosteroids, Symptoms Score

(2021) Luis Pérez de Llano et al.   Journal of Allergy and Clinical Immunology-In Practice

Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression

(2021) Corrado Pelaia et al.   Journal of Asthma and Allergy

Eosinophilic and non-eosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort

(2021) Liam G. Heaney et al.   CHEST

Monoclonal antibody treatment for severe uncontrolled asthma in Spain: analytical map

(2021) Francisco Casas-Maldonado et al.   JOURNAL OF ASTHMA

Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study

(2021) Santi Nolasco et al.   Journal of Allergy and Clinical Immunology-In Practice

Effectiveness of Switching Biologics for Severe Asthma Patients in Japan: A Single-Center Retrospective Study

(2021) Takanori Numata et al.   Journal of Asthma and Allergy

Comparability of asthma control test scores between self and physician-administered test

(2020) Claudia Crimi et al.   RESPIRATORY MEDICINE

EAACI Biologicals Guidelines—Recommendations for severe asthma

(2020) Ioana Agache et al.   ALLERGY

Long-term therapy response to anti-interleukin-5 biologics in severe asthma – a real-life evaluation

(2020) Katrien Eger et al.   Journal of Allergy and Clinical Immunology-In Practice

Clinical outcomes and healthcare resource utilization associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice

(2020) Michael E. Wechsler et al.   CHEST

Efficacy and safety of reslizumab in severe asthma patients with inadequate response to omalizumab: a multicentre, open-label, pilot study

(2019) Luis A. Pérez de Llano et al.   Journal of Allergy and Clinical Immunology-In Practice

Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: the COSMEX Study

(2019) Sandhya Khurana et al.   CLINICAL THERAPEUTICS

An expert consensus framework for asthma remission as a treatment goal

(2019) Andrew Menzies-Gow et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

(2017) Theo Vos et al.   LANCET

Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study

(2016) Njira Lugogo et al.   CLINICAL THERAPEUTICS

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

(2015) Mario Castro et al.   Lancet Respiratory Medicine

Severe adult-onset asthma: A distinct phenotype

(2013) Marijke Amelink et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Measurement and Rates of Persistence With and Adherence to Biologics for Rheumatoid Arthritis: A Systematic Review

(2011) Marissa A. Blum et al.   CLINICAL THERAPEUTICS